In contrast, this reply to the paper states:
In conclusion, regardless of whether BiP levels are differentially regulated in different infection models or at different time points p.i., there is, in our opinion, currently not enough evidence to suggest that a combined treatment using established anti SARS-CoV-2 therapeutics (or emerging compounds such as thapsigargin) and anti-GRP78 (BiP) compounds will have an additive or synergistic effect in suppressing SARS-CoV-2 replication. We consider it more likely that this sort of combination therapy results in increased cytotoxicity. Clearly, more experimental and pre-clinical work is needed to support this concept.
I'm starting to realize here that essentially all posts make claims that aren't supposed by the papers posted.